Novo Nordisk A/s

Agouron Pharmaceuticals, Inc.

Dan Kiel

Min Teng

Michael David Johnson

Jesper F Lau

Peter Madsen

Yufeng Hong

Vlad Edward Gregor

Anthony Lai Ling

Javier Gonzalez

Larry Kenneth Truesdale

Atsuo Kuki

Jun Feng

Preben H Olesen

Janos Tibor Kodra

Christian Klarner Sams

Carsten Behrens

Daljit Singh Dhanoa

Anker S Jorgensen

Michael Bruno Plewe

Lars Naerum

Dilip Ramakant Bhumralkar

Shenghua Shi

Liselotte Bjerre Knudsen

Christine Thomas

Ulla Grove Sidelmann

Lotte Bjerre Knudsen

Ingrid Petterson

Johannes Cornelis De Jong

Ranjan Jagath Rajapakse

Richard A Bychowski

Kimberly Ann Teston

Tso-sheng Chou

Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.

Non-peptide GLP-1 agonists

Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.

Glucagon antagonists/inverse agonists

Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent activation of the receptor by bound GLP-1. The invention further relates to a method of inhibiting the binding of GLP-1 to the GLP-1 receptor and a method of inhibiting the activation of the GLP-1 receptor. Intermediate compounds useful for making non-peptide GLP-1 receptor antagonists are also described.

Non-peptide antagonists of GLP-1 receptor and methods of use

Growing community of inventors

San Diego, CA, United States of America

Dan Kiel